Clinical trial · Interventional
Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies
Phase II Trial of Fludarabine Combined With Intravenous Thiotepa and Allogeneic Hematopoietic Stem-cell Transplantation in Patients With Lymphatic Malignancies Including Multiple Myeloma, Non Hodgkin's, Hodgkin Lymphoma and CLL
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study hypotheses is that the introduction of dose escalated thiotepa, in substitution to busulfan or melphalan, will reduce toxicity after allogeneic transplantation while improving disease eradication in patients with lymphoid malignancies not eligible for standard transplantation.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | ONTOLOGY_EXACT | 0.98 |
| Hodgkin Lymphoma | Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
| Non Hodgkin Lymphoma | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Thiotepa | Drug | Thiotepa | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- thiotepa
- description
- Thiotepa 5-10 mg/kg/d x 2 days
- interventionNames
- Drug: Thiotepa
Primary outcomes (1)
- measure
- disease-free survival
- timeFrame
- 2 years after transplantation
- description
- The percentage of patients alive without disease recurrence 2 years after transplant
Secondary outcomes (3)
- measure
- treatment-related mortality
- timeFrame
- 2 years after transplantation
- description
- The percentage of patients who die of complications related to the transplant
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 68 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age less than physiologic 68 years. 2. Patients with MM, NHL, HL and CLL with an indication for allogeneic transplantation as follows: 1. MM; patients relapsing after autologous transplant or with high-risk cytogenetic abnormalities 2. Aggressive lymphoma and Hodgkin lymphoma; relapse after autologous transplants 3. Follicular lymphoma; failure of at least one prior regimen 4. CLL; failure of prior therapy which includes Fludarabine combinations or 17p- cytogenetic abnormality 3. Patients must have an HLA matched related or unrelated donor willing to donate either peripheral blood stem cells or bone marrow. Matching is based on high-resolution class I (HLA-A, -B, -C) and class II (HLA-DRB1, -DQB) typing. The goal is to transplant \> 3 x 106 CD34+ cells per kg body weight of the recipient 4. Patients must sign written informed consent. 5. Adequate birth control in fertile patients. Exclusion Criteria: 1. Bilirubin \> 3.0 mg/dl, transaminases \> 3 times upper normal limit 2. Creatinine \> 2.0 mg/dl 3. ECOG-Performance status \> 2 4. Uncontrolled infection 5. Pregnancy or lactation 6. Abnormal lung diffusion capacity (DLCO \< 40% predicted) 7. Severe cardiovascular disease 8. CNS disease involvement 9. Pleural effusion or ascites \> 1 liter 10. Known hypersensitivity to Fludarabine or treosulfan 11. Psychiatric conditions/disease that impair the ability to give informed consent or to adequately co-operate
References
Publications (0)
Data not yet available